Navigation Links
Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Date:4/26/2012

2012 as a result of higher prescription demand, due to an increase in VYVANSE's market share and growth in the US ADHD market (+10%), and the effect of a price increase taken since Q1 2011. These positive factors were partially offset by higher sales deductions as a percentage of gross product sales in Q1 2012 compared to Q1 2011.

REPLAGAL - Fabry disease

REPLAGAL product sales growth was driven by the treatment of new patients, being both naïve patients and switches from FABRAZYME®. Reported REPLAGAL sales were impacted by unfavourable foreign exchange, due to the stronger US dollar in Q1 2012 compared to Q1 2011.

ELAPRASE- Hunter syndrome

Product sales for ELAPRASE increased as a result of increased patients on therapy across all regions in which ELAPRASE is sold and also benefited from the timing of certain large orders from markets which order less frequently. Reported ELAPRASE sales were also impacted by unfavourable foreign exchange.

ADDERALL XR - ADHD

ADDERALL XR product sales in Q1 2012 remained constant compared with Q1 2011, as higher US prescription demand was offset by an increase in sales deductions in Q1 2012.

For the full year we expect ADDERALL XR's sales deductions as a percentage of branded gross sales to be between 60% and 65%.

LIALDA/MEZAVANT - Ulcerative colitis

The growth in product sales for LIALDA/MEZAVANT in Q1 2012 primarily resulted from higher US prescription demand following increases in US market share and a price increase taken since Q1 2011, offset by higher de-stocking in Q1 2012 compared to Q1 2011.

VPRIV - Gaucher disease

VPRIV product sales growth was driven by the treatment of new patients, being both naïve patients and switches from CEREZYME®. Reported VPRIV sales were also impacted by unfavourable foreign exchange.

INTUNIV - ADHD

INTUNIV product sales were up 63% compared to Q1 2011,
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Reportlinker.com announces that a new ... Asia-Pacific Infusion Therapy Device Market ... Abstract: The Asia-Pacific ... infusion pumps, syringe infusion pumps, disposable infusion pumps, ... categories are segmented based on the type of ...
(Date:9/2/2014)... The Pharmaceutical Care Management Association (PCMA), the national association ... lawsuit in Iowa federal court ... law that restricts tools used by PBMs to lower ... The law—HF 2297—forces PBMs to overpay ... Maximum Allowable Cost (MAC) lists that keep generic drug ...
(Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
Breaking Medicine Technology:Asia-Pacific Infusion Therapy Device Market 2Asia-Pacific Infusion Therapy Device Market 3Asia-Pacific Infusion Therapy Device Market 4Asia-Pacific Infusion Therapy Device Market 5Asia-Pacific Infusion Therapy Device Market 6Asia-Pacific Infusion Therapy Device Market 7Asia-Pacific Infusion Therapy Device Market 8Asia-Pacific Infusion Therapy Device Market 9Asia-Pacific Infusion Therapy Device Market 10Asia-Pacific Infusion Therapy Device Market 11Asia-Pacific Infusion Therapy Device Market 12Asia-Pacific Infusion Therapy Device Market 13Asia-Pacific Infusion Therapy Device Market 14Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... Oct. 20 Premier Research Group Limited, the international ... of Bernard Sweeney as Executive Director, Medical Devices. In ... in the operations, strategic planning, and corporate development of ... will be based in Premier Research,s Swiss office. , ...
... 20 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), ... Investor Conference at 11:30 a.m. Pacific Time on October ... San Diego, California. , ISTA,s Chief Financial Officer, Lauren ... and clinical progress. To access the live audio broadcast, ...
Cached Medicine Technology:Premier Research Names Bernard Sweeney as Executive Director, Medical Devices 2
(Date:9/2/2014)... Germany, September 2, 2014 In a large ... researchers found that mild cognitive impairment (MCI) occurred ... mellitus type 2. Interestingly, this strong association was ... in older participants (66-80 years) the association vanished. ... of Alzheimer,s Disease . , The concept of ...
(Date:9/2/2014)... Melbourne, Australia (PRWEB) September 03, 2014 ... Australia attend to millions of people annually, arranging care ... subdivision's not-for-profit and private enterprises are expected to derive ... government funding, donations and private income. Over the five ... at an annualised rate of 6.6%, including growth of ...
(Date:9/2/2014)... Steven Reinberg HealthDay ... A device intended to help with weight loss by blocking ... meet expectations in a trial among obese patients. Using ... the brain and stomach, researchers hoped to suppress feelings of ... anticipated. "A device that safely blocks the nerve that ...
(Date:9/2/2014)... Doctors trained in locations with less intensive (and expensive) ... clinical decisions that spare patients unnecessary and excessive medical ... Internal Medicine . , "Growing concern about the costs ... assessing physicians, ability to avoid the provision of unnecessary ... Outcomes Group and The Dartmouth Institute for Health ...
(Date:9/2/2014)... Last year, SIGVARIS took graduated ... of a luxurious line of graduated compression socks with natural ... COTTON Socks are joining the SIGVARIS MEDICAL collection for those ... comfort of natural cotton fibers. , “When people step ... find socks as soft as the finest cashmere,” says Clay ...
Breaking Medicine News(10 mins):Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2
... a few millimeters, depends on a supply of nutrients ... vascular wall cells of neighboring blood vessels to sprout ... blood circulation. , This process called angiogenesis involves ... receptors on the vascular wall cells. The departments of ...
... birds in the tropics look like they,re a drag to ... experiments by University of California, Berkeley, biologists shows that they ... at least in hummingbirds. , "We estimate that having a ... to 3 percent, which means the bird has to visit ...
... will help 5,000 more impoverished children in ... 2009 Best Picture "Slumdog Millionaire" shines the ... in India. Children International answers ... center to help poor children in Calcutta.To ...
... RALEIGH, N.C., March 12 MedThink Communications, a ... doctorate-level associate scientific director to support its rapidly ... two scientific directors at MedThink who provide high-level ... clients. With a team of seven doctorate-level medical ...
... study finds , , THURSDAY, March 12 (HealthDay News) ... testing athletes, because current tests ignore important ethnic ... and other hormones that increase testosterone levels are ... used in sports, according to the World Anti-Doping ...
... Highlights- Revenue: $35.7 million, up 19% from $29.9 million ... Q4,07LAWRENCE, Mass., March 12 NxStage Medical, Inc. (Nasdaq: ... dialysis products, today reported financial results for the three ... included revenue and Adjusted EBITDA results above the top ...
Cached Medicine News:Health News:A new measure for the malignancy of melanoma 2Health News:Long, sexy tails not a drag on male birds 2Health News:Long, sexy tails not a drag on male birds 3Health News:Long, sexy tails not a drag on male birds 4Health News:Photos: Children International Opens Center to Help Poor Children in India 2Health News:MedThink Hires Associate Scientific Director to Support Its Growing Health Care Clientele 2Health News:European Researchers Call for New Doping Standards 2Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 9Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 10Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 11
Polyester ribbons (3) impregnated with different OD values of conjugated Protein A...
Polyester ribbon impregnated with conjugated Protein A - .13 OD per sq. cm....
Polyester ribbon impregnated with conjugated Protein A - .25 OD per sq. cm....
Colloidal Gold Conjugated, Protein A - 12 OD...
Medicine Products: